

Jesse Joshua Smith

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8396481/publications.pdf>

Version: 2024-02-01

129
papers

9,319
citations

76326

40
h-index

46799

89
g-index

132
all docs

132
docs citations

132
times ranked

11759
citing authors

#	ARTICLE	IF	CITATIONS
1	A SMAD4 -modulated gene profile predicts disease-free survival in stage II and III colorectal cancer. <i>Cancer Reports</i> , 2022, 5, e1423.	1.4	10
2	Genomic Stratification of Resectable Colorectal Liver Metastasis Patients and Implications for Adjuvant Therapy and Survival. <i>Annals of Surgery</i> , 2022, 275, 371-381.	4.2	4
3	The Paradox of Early Stage Rectal Cancer: More ReSeARCh in the Right Direction. <i>Annals of Surgical Oncology</i> , 2022, 29, 1513-1515.	1.5	0
4	MRI at Restaging After Neoadjuvant Therapy for Rectal Cancer Overestimates Circumferential Resection Margin Proximity as Determined by Comparison With Whole-Mount Pathology. <i>Diseases of the Colon and Rectum</i> , 2022, 65, 489-496.	1.3	9
5	Survival After Induction Chemotherapy and Chemoradiation Versus Chemoradiation and Adjuvant Chemotherapy for Locally Advanced Rectal Cancer. <i>Oncologist</i> , 2022, 27, 380-388.	3.7	12
6	Transcriptomic profiling to identify subsets of immune hot locally advanced rectal adenocarcinomas with favorable outcomes after neoadjuvant treatment.. <i>Journal of Clinical Oncology</i> , 2022, 40, 155-155.	1.6	0
7	Unresected Left-sided Colon Tumors in Asymptomatic Metastatic Patients are Associated with Higher Rates of Complications than Unresected Right-sided Tumors. <i>European Journal of Surgical Oncology</i> , 2022, 48, e48.	1.0	0
8	KRAS Mutants Upregulate Integrin β 4 to Promote Invasion and Metastasis in Colorectal Cancer. <i>Molecular Cancer Research</i> , 2022, 20, 1305-1319.	3.4	3
9	Neoadjuvant Therapy for Rectal Cancer. <i>Surgical Oncology Clinics of North America</i> , 2022, 31, 279-291.	1.5	3
10	Programme of self-reactive innate-like T cell-mediated cancer immunity. <i>Nature</i> , 2022, 605, 139-145.	27.8	38
11	Colorectal Cancer Develops Inherent Radiosensitivity That Can Be Predicted Using Patient-Derived Organoids. <i>Cancer Research</i> , 2022, 82, 2298-2312.	0.9	14
12	Nonoperative Management for Rectal Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2022, 36, 539-551.	2.2	5
13	Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy. <i>Journal of Clinical Oncology</i> , 2022, 40, 2546-2556.	1.6	292
14	PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 2363-2376.	27.0	588
15	Predictors of operative difficulty in robotic low anterior resection for rectal cancer. <i>Colorectal Disease</i> , 2022, 24, 1318-1324.	1.4	2
16	Intraoperative opioids are associated with decreased recurrence rates in colon adenocarcinoma: a retrospective observational cohort study. <i>British Journal of Anaesthesia</i> , 2022, 129, 172-181.	3.4	9
17	Non-Operative Management of Patients with Rectal Cancer: Lessons Learnt from the OPRA Trial. <i>Cancers</i> , 2022, 14, 3204.	3.7	11
18	Primary Tumor-Related Complications and Salvage Outcomes in Patients with Metastatic Rectal Cancer and an Untreated Primary Tumor. <i>Diseases of the Colon and Rectum</i> , 2021, 64, 45-52.	1.3	7

#	ARTICLE	IF	CITATIONS
19	The association between tumor mutational burden and prognosis is dependent on treatment context. <i>Nature Genetics</i> , 2021, 53, 11-15.	21.4	139
20	Feasibility and performance of the fecal immunochemical test (FIT) for average-risk colorectal cancer screening in Nigeria. <i>PLoS ONE</i> , 2021, 16, e0243587.	2.5	9
21	Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. <i>Nature Communications</i> , 2021, 12, 729.	12.8	212
22	Evaluating the Validity of the Clavien-Dindo Classification in Colectomy Studies: A 90-Day Cost of Care Analysis. <i>Diseases of the Colon and Rectum</i> , 2021, 64, 1426-1434.	1.3	8
23	Clinical Calculator Based on Molecular and Clinicopathologic Characteristics Predicts Recurrence Following Resection of Stage I-III Colon Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 911-919.	1.6	34
24	KRAS mutant rectal cancer cells interact with surrounding fibroblasts to deplete the extracellular matrix. <i>Molecular Oncology</i> , 2021, 15, 2766-2781.	4.6	7
25	To resect or not to resect? Insight on managing the asymptomatic primary tumor in colorectal cancer patients with synchronous unresectable metastases from the prospective Japan Clinical Oncology Group Trial. <i>Surgery</i> , 2021, 170, 1856-1857.	1.9	0
26	Type of recurrence is associated with disease-free survival after salvage surgery for locally recurrent rectal cancer. <i>International Journal of Colorectal Disease</i> , 2021, 36, 2603-2611.	2.2	7
27	A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1683-1692.	6.3	66
28	Cancer Clinical Trials in Africa—An Untapped Opportunity: Recommendations From AORTIC 2019 Conference Special Interest Group in Clinical Trials. <i>JCO Global Oncology</i> , 2021, 7, 1358-1363.	1.8	11
29	A Claudin-Based Molecular Signature Identifies High-Risk, Chemoresistant Colorectal Cancer Patients. <i>Cells</i> , 2021, 10, 2211.	4.1	10
30	International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 805-816.	27.6	93
31	Organ Preservation in Patients with Rectal Cancer Treated with Total Neoadjuvant Therapy. <i>Diseases of the Colon and Rectum</i> , 2021, 64, 1463-1470.	1.3	22
32	Climbing the grants ladder: Funding opportunities for surgeons. <i>Surgery</i> , 2021, 170, 707-712.	1.9	2
33	Options for Low Rectal Cancer: Robotic Total Mesorectal Excision. <i>Clinics in Colon and Rectal Surgery</i> , 2021, 34, 311-316.	1.1	0
34	Anorectal Mucosal Melanoma in the Era of Immune Checkpoint Inhibition: Should We Change Our Surgical Management Paradigm?. <i>Diseases of the Colon and Rectum</i> , 2021, 64, 555-562.	1.3	8
35	Adoption of Organ Preservation and Surgeon Variability for Patients with Rectal Cancer Does Not Correlate with Worse Survival. <i>Annals of Surgical Oncology</i> , 2021, , 1.	1.5	4
36	ASO Visual Abstract: Adoption of Organ Preservation and Surgeon Variability for Patients with Rectal Cancer Does Not Correlate with Worse Survival. <i>Annals of Surgical Oncology</i> , 2021, , 1.	1.5	0

#	ARTICLE	IF	CITATIONS
37	Molecular and phenotypic profiling of colorectal cancer patients in West Africa reveals biological insights. <i>Nature Communications</i> , 2021, 12, 6821.	12.8	15
38	Development and Assessment of a Clinical Calculator for Estimating the Likelihood of Recurrence and Survival Among Patients With Locally Advanced Rectal Cancer Treated With Chemotherapy, Radiotherapy, and Surgery. <i>JAMA Network Open</i> , 2021, 4, e2133457.	5.9	16
39	Identifying Diagnostic MicroRNAs and Investigating Their Biological Implications in Rectal Cancer. <i>JAMA Network Open</i> , 2021, 4, e2136913.	5.9	3
40	Comparing outcomes of robotic <i>versus</i> open mesorectal excision for rectal cancer. <i>BJS Open</i> , 2021, 5, .	1.7	6
41	Discordant DNA mismatch repair protein status between synchronous or metachronous gastrointestinal carcinomas: frequency, patterns, and molecular etiologies. <i>Familial Cancer</i> , 2020, 20, 201-213.	1.9	8
42	Quantitative assessment of tumor-infiltrating lymphocytes in mismatch repair proficient colon cancer. <i>Oncolmmunology</i> , 2020, 9, 1841948.	4.6	3
43	Mismatch Repair-Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 3271-3279.	7.0	118
44	Patient-Reported Bowel Function in Patients With Rectal Cancer Managed by a Watch-and-Wait Strategy After Neoadjuvant Therapy: A Case-Control Study. <i>Diseases of the Colon and Rectum</i> , 2020, 63, 897-902.	1.3	41
45	Risk of Metachronous Colorectal Neoplasm after a Segmental Colectomy in Lynch Syndrome Patients According to Mismatch Repair Gene Status. <i>Journal of the American College of Surgeons</i> , 2020, 230, 669-675.	0.5	16
46	Coaltered <i>Ras/B-raf</i> and <i>TP53</i> Is Associated with Extremes of Survivorship and Distinct Patterns of Metastasis in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1077-1085.	7.0	62
47	Watch and Wait in Rectal Cancer or More Wait and See?. <i>JAMA Surgery</i> , 2020, 155, 657.	4.3	18
48	Intracorporeal Anastomoses in Minimally Invasive Right Colectomies Are Associated With Fewer Incisional Hernias and Shorter Length of Stay. <i>Diseases of the Colon and Rectum</i> , 2020, 63, 685-692.	1.3	40
49	Management of Locally Advanced Rectal Cancer During The COVID-19 Pandemic: A Necessary Paradigm Change at Memorial Sloan Kettering Cancer Center. <i>Advances in Radiation Oncology</i> , 2020, 5, 687-689.	1.2	33
50	A phase II study of induction PD-1 blockade in subjects with locally advanced mismatch repair-deficient rectal adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS4123-TPS4123.	1.6	3
51	Genomic characterization of rectal cancer and molecular determinants of response to neoadjuvant chemoradiotherapy.. <i>Journal of Clinical Oncology</i> , 2020, 38, 192-192.	1.6	0
52	Does Intentional Support of Degree Programs in General Surgery Residency Affect Research Productivity or Pursuit of Academic Surgery? A Multi-Institutional Study. <i>Journal of Surgical Education</i> , 2020, 77, e34-e38.	2.5	5
53	Monitoring an Ongoing Enhanced Recovery After Surgery (ERAS) Program: Adherence Improves Clinical Outcomes in a Comparison of Three Thousand Colorectal Cases. <i>Clinics in Surgery</i> , 2020, 5, .	0.8	3
54	Looking Forward, Not Backward, on Watch and Wait for Rectal Cancer-Reply. <i>JAMA Oncology</i> , 2019, 5, 1231.	7.1	2

#	ARTICLE	IF	CITATIONS
55	Mathematical Modeling of the Metastatic Colorectal Cancer Microenvironment Defines the Importance of Cytotoxic Lymphocyte Infiltration and Presence of PD-L1 on Antigen Presenting Cells. <i>Annals of Surgical Oncology</i> , 2019, 26, 2821-2830.	1.5	21
56	Genomic stratification beyond Ras/Bâ€Raf in colorectal liver metastasis patients treated with hepatic arterial infusion. <i>Cancer Medicine</i> , 2019, 8, 6538-6548.	2.8	8
57	Initial Results of the First Clinical Trial of a Novel Unidirectional Permanent Device for Intraoperative Brachytherapy. <i>Brachytherapy</i> , 2019, 18, S30.	0.5	0
58	A rectal cancer organoid platform to study individual responses to chemoradiation. <i>Nature Medicine</i> , 2019, 25, 1607-1614.	30.7	320
59	Blood vessel epicardial substance reduces LRP6 receptor and cytoplasmic Î²-catenin levels to modulate Wnt signaling and intestinal homeostasis. <i>Carcinogenesis</i> , 2019, 40, 1086-1098.	2.8	11
60	Contemporary Validation of a Nomogram Predicting Colon Cancer Recurrence, Revealing All-Stage Improved Outcomes. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz015.	2.9	16
61	Assessment of the Value of Comorbidity Indices for Risk Adjustment in Colorectal Surgery Patients. <i>Annals of Surgical Oncology</i> , 2019, 26, 2797-2804.	1.5	13
62	Role of the Interval from Completion of Neoadjuvant Therapy to Surgery in Postoperative Morbidity in Patients with Locally Advanced Rectal Cancer. <i>Annals of Surgical Oncology</i> , 2019, 26, 2019-2027.	1.5	15
63	Watch and Wait in Rectal Cancer Patients with Clinical Complete Response to Neoadjuvant Therapy: The American Viewpoint. , 2019, , 195-211.		0
64	Variation in the Thoroughness of Pathologic Assessment and Response Rates of Locally Advanced Rectal Cancers After Chemoradiation. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 794-799.	1.7	2
65	Adjuvant Chemotherapy for Colon Cancer. <i>Diseases of the Colon and Rectum</i> , 2019, 62, 274-278.	1.3	6
66	Cellular localization of PD-L1 expression in mismatch-repair-deficient and proficient colorectal carcinomas. <i>Modern Pathology</i> , 2019, 32, 110-121.	5.5	28
67	SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance. <i>Clinical Cancer Research</i> , 2019, 25, 1948-1956.	7.0	71
68	Assessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients With a Complete Response After Neoadjuvant Therapy. <i>JAMA Oncology</i> , 2019, 5, e185896.	7.1	347
69	Effect of Neoadjuvant Systemic Chemotherapy With or Without Chemoradiation on Bowel Function in Rectal Cancer Patients Treated With Total Mesorectal Excision. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 800-807.	1.7	21
70	Use of the Xi robotic platform for total abdominal colectomy: a step forward in minimally invasive colorectal surgery. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2019, 33, 966-971.	2.4	15
71	Value of adding dynamic contrast-enhanced MRI visual assessment to conventional MRI and clinical assessment in the diagnosis of complete tumour response to chemoradiotherapy for rectal cancer. <i>European Radiology</i> , 2019, 29, 1104-1113.	4.5	23
72	Review: KRAS mutations are influential in driving hepatic metastases and predicting outcome in colorectal cancer. <i>Chinese Clinical Oncology</i> , 2019, 8, 53-53.	1.2	8

#	ARTICLE	IF	CITATIONS
73	Organ preservation in rectal cancer patients treated with total neoadjuvant therapy.. Journal of Clinical Oncology, 2019, 37, 692-692.	1.6	0
74	KRAS mutation is associated with upregulation of integrin beta-4 expression leading to tumor invasion in colorectal cancer.. Journal of Clinical Oncology, 2019, 37, 576-576.	1.6	1
75	Poorly Differentiated Clusters Predict Colon Cancer Recurrence. American Journal of Surgical Pathology, 2018, 42, 705-714.	3.7	61
76	Association of Preoperative and Postoperative Serum Carcinoembryonic Antigen and Colon Cancer Outcome. JAMA Oncology, 2018, 4, 309.	7.1	146
77	Clinical Value of CT Colonography Versus Preoperative Colonoscopy in the Surgical Management of Occlusive Colorectal Cancer. American Journal of Roentgenology, 2018, 210, 333-340.	2.2	15
78	Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. JAMA Oncology, 2018, 4, e180071.	7.1	404
79	Spatial and phenotypic immune profiling of metastatic colon cancer. JCI Insight, 2018, 3, .	5.0	73
80	Epithelial Smad4 Deletion Up-Regulates Inflammation and Promotes Inflammation-Associated Cancer. Cellular and Molecular Gastroenterology and Hepatology, 2018, 6, 257-276.	4.5	50
81	Effectiveness of a multidisciplinary patient care bundle for reducing surgical-site infections. British Journal of Surgery, 2018, 105, 1680-1687.	0.3	57
82	MASTL induces Colon Cancer progression and Chemoresistance by promoting Wnt/ β -catenin signaling. Molecular Cancer, 2018, 17, 111.	19.2	59
83	BVES regulates c-Myc stability via PP2A and suppresses colitis-induced tumourigenesis. Gut, 2017, 66, 852-862.	12.1	43
84	Single Nucleotide Polymorphism TGF β 1 R25P Correlates with Acute Toxicity during Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2017, 97, 924-930.	0.8	10
85	Lymph node yield in right colectomy for cancer: a comparison of open, laparoscopic and robotic approaches. Colorectal Disease, 2017, 19, 888-894.	1.4	46
86	Preliminary Clinical Experience from a Phase I Feasibility Study of a Novel Permanent Unidirectional Intraoperative Brachytherapy Device. Brachytherapy, 2017, 16, S48.	0.5	1
87	MTG16 is a tumor suppressor in colitis-associated carcinoma. JCI Insight, 2017, 2, .	5.0	6
88	Extraordinary survivorship after colorectal liver metastasis resection to identify a distinct molecular profile associated with survival in an independent cohort of 965 patients.. Journal of Clinical Oncology, 2017, 35, 3581-3581.	1.6	0
89	Total neoadjuvant chemotherapy to facilitate delivery and tolerance of systemic chemotherapy and response in locally advanced rectal cancer.. Journal of Clinical Oncology, 2017, 35, 3519-3519.	1.6	4
90	Integrated genomic profiling identifies microRNA-mediated regulation of IQGAP2 in locally advanced rectal cancer. Genes Chromosomes and Cancer, 2016, 55, 311-321.	2.8	9

#	ARTICLE	IF	CITATIONS
91	KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy. <i>Annals of Surgical Oncology</i> , 2016, 23, 2548-2555.	1.5	70
92	Distance to the anal verge is associated with pathologic complete response to neoadjuvant therapy in locally advanced rectal cancer. <i>Journal of Surgical Oncology</i> , 2016, 114, 637-641.	1.7	35
93	Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma. <i>Modern Pathology</i> , 2016, 29, 1433-1442.	5.5	144
94	Myeloid translocation genes differentially regulate colorectal cancer programs. <i>Oncogene</i> , 2016, 35, 6341-6349.	5.9	11
95	Cytoreductive surgery and intraperitoneal chemotherapy: an evidence-based review-past, present and future. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 143-57.	1.4	37
96	Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management. <i>BMC Cancer</i> , 2015, 15, 767.	2.6	276
97	Hepatic Uterus-Like Mass Misdiagnosed as Hepatic Abscess. <i>International Journal of Surgical Pathology</i> , 2015, 23, 134-139.	0.8	17
98	Claudin-7 expression induces mesenchymal to epithelial transformation (MET) to inhibit colon tumorigenesis. <i>Oncogene</i> , 2015, 34, 4570-4580.	5.9	75
99	Advances and Challenges in Treatment of Locally Advanced Rectal Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1797-1808.	1.6	150
100	Nomograms in oncology: more than meets the eye. <i>Lancet Oncology</i> , The, 2015, 16, e173-e180.	10.7	2,187
101	ERBB4 is over-expressed in human colon cancer and enhances cellular transformation. <i>Carcinogenesis</i> , 2015, 36, 710-718.	2.8	81
102	Surgical Management of Hepatic Metastases of Colorectal Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 61-84.	2.2	56
103	Transanal surgery for cT1 rectal cancer: Patient selection, technique, and outcomes. <i>Seminars in Colon and Rectal Surgery</i> , 2015, 26, 20-25.	0.3	1
104	Organ preservation in patients with rectal cancer with clinical complete response after neoadjuvant therapy. <i>Journal of Clinical Oncology</i> , 2015, 33, 509-509.	1.6	22
105	Outcomes in non-metastatic colorectal cancer. <i>Journal of Surgical Oncology</i> , 2014, 110, 518-526.	1.7	5
106	Does Intentional Support of Degree Programs in General Surgery Residency Affect Research Productivity or Pursuit of Academic Surgery?. <i>Journal of Surgical Education</i> , 2014, 71, 486-491.	2.5	27
107	Can We Predict Response and/or Resistance to Neoadjuvant Chemoradiotherapy in Patients with Rectal Cancer?. <i>Current Colorectal Cancer Reports</i> , 2014, 10, 164-172.	0.5	4
108	Toxic Nodular Goiter and Cancer: A Compelling Case for Thyroidectomy. <i>Annals of Surgical Oncology</i> , 2013, 20, 1336-1340.	1.5	37

#	ARTICLE	IF	CITATIONS
109	Cancer after Thyroidectomy: A Multi-Institutional Experience with 1,523 Patients. <i>Journal of the American College of Surgeons</i> , 2013, 216, 571-577.	0.5	62
110	Tumor Suppressor Function of the Plasma Glutathione Peroxidase Gpx3 in Colitis-Associated Carcinoma. <i>Cancer Research</i> , 2013, 73, 1245-1255.	0.9	155
111	A Smad4-modulated Wnt target gene expression profile identifies high-risk colorectal cancer patients. <i>Journal of the American College of Surgeons</i> , 2012, 215, S30-S31.	0.5	0
112	Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancer. <i>Gut</i> , 2012, 61, 1291-1298.	12.1	74
113	Smad4-Mediated Signaling Inhibits Intestinal Neoplasia by Inhibiting Expression of β -Catenin. <i>Gastroenterology</i> , 2012, 142, 562-571.e2.	1.3	156
114	Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. <i>Nature Medicine</i> , 2012, 18, 1052-1059.	30.7	219
115	Kaiso Directs the Transcriptional Corepressor MTC16 to the Kaiso Binding Site in Target Promoters. <i>PLoS ONE</i> , 2012, 7, e51205.	2.5	22
116	Claudin-1 Up-regulates the Repressor ZEB-1 to Inhibit E-Cadherin Expression in Colon Cancer Cells. <i>Gastroenterology</i> , 2011, 141, 2140-2153.	1.3	143
117	Claudin-2 expression increases tumorigenicity of colon cancer cells: role of epidermal growth factor receptor activation. <i>Oncogene</i> , 2011, 30, 3234-3247.	5.9	133
118	BVES regulates EMT in human corneal and colon cancer cells and is silenced via promoter methylation in human colorectal carcinoma. <i>Journal of Clinical Investigation</i> , 2011, 121, 4056-4069.	8.2	60
119	Targeting Angiogenesis in the Treatment of Hepatic Metastasis. <i>Cancer Metastasis - Biology and Treatment</i> , 2011, , 417-430.	0.1	0
120	HDAC inhibitors regulate claudin-1 expression in colon cancer cells through modulation of mRNA stability. <i>Oncogene</i> , 2010, 29, 305-312.	5.9	83
121	Targeted Inhibition of Src Kinase Signaling Attenuates Pancreatic Tumorigenesis. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 2322-2332.	4.1	89
122	Experimentally Derived Metastasis Gene Expression Profile Predicts Recurrence and Death in Patients With Colon Cancer. <i>Gastroenterology</i> , 2010, 138, 958-968.	1.3	576
123	Loss of Rab25 promotes the development of intestinal neoplasia in mice and is associated with human colorectal adenocarcinomas. <i>Journal of Clinical Investigation</i> , 2010, 120, 840-849.	8.2	134
124	Regulation of metastasis in colorectal adenocarcinoma: A collision between development and tumor biology. <i>Surgery</i> , 2008, 144, 353-366.	1.9	24
125	47. Microarray Analysis of Smad4 Gene Expression and Impact On Survival in Human Colorectal Cancer. <i>Journal of Surgical Research</i> , 2008, 144, 196-197.	1.6	1
126	Oncogenic Ras and Transforming Growth Factor- β Synergistically Regulate AU-Rich Element-Containing mRNAs during Epithelial to Mesenchymal Transition. <i>Molecular Cancer Research</i> , 2008, 6, 1124-1136.	3.4	38

#	ARTICLE	IF	CITATIONS
127	Carotid Body Tumor Resection: Does the Need for Vascular Reconstruction Worsen Outcome?. Annals of Vascular Surgery, 2006, 20, 435-439.	0.9	45
128	Endovascular Treatment of Mycotic Aneurysms of the Thoracic and Abdominal Aorta: The Need for Level I Evidence. European Journal of Vascular and Endovascular Surgery, 2004, 27, 569-570.	1.5	52
129	Cold visceral perfusion improves early survival in patients with acute renal failure after thoracoabdominal aortic aneurysm repair. Journal of Vascular Surgery, 2004, 39, 506-512.	1.1	75